Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for bioAffinity Technologies (BIAF) over the last 3 years, with Q3 2025 value amounting to $3646.0.

  • bioAffinity Technologies' Cash from Investing Activities rose 13874.6% to $3646.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$60568.0, marking a year-over-year increase of 772.7%. This contributed to the annual value of -$79083.0 for FY2024, which is 9642.06% up from last year.
  • Per bioAffinity Technologies' latest filing, its Cash from Investing Activities stood at $3646.0 for Q3 2025, which was up 13874.6% from -$13427.0 recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Cash from Investing Activities ranged from a high of $13442.0 in Q4 2023 and a low of -$2.2 million during Q3 2023
  • Moreover, its 3-year median value for Cash from Investing Activities was -$13427.0 (2025), whereas its average is -$213549.9.
  • Per our database at Business Quant, bioAffinity Technologies' Cash from Investing Activities crashed by 63258.22% in 2024 and then surged by 13874.6% in 2025.
  • Over the past 3 years, bioAffinity Technologies' Cash from Investing Activities (Quarter) stood at $13442.0 in 2023, then plummeted by 100.01% to -$1.0 in 2024, then skyrocketed by 364700.0% to $3646.0 in 2025.
  • Its last three reported values are $3646.0 in Q3 2025, -$13427.0 for Q2 2025, and -$50786.0 during Q1 2025.